MDxHealth SA Posts 18% Revenue Growth in Q3 2025, Maintains Revenue Guidance Amid Acquisition and Integration Challenges

MDxHealth SA reported an 18% revenue growth in Q3 2025, reaching $27.4 million. The company achieved a positive adjusted EBITDA of $1 million, marking its second consecutive profitable quarter. The acquisition of the exosome diagnostics business positions MDxHealth SA as a leader in precision diagnostics in urology. However, the company foregoes its planned germline offering, impacting expected revenue contributions for the second half of the year. Despite the acquisition, MDxHealth SA maintained its revenue guidance.